Blueprint Medicines
Blueprint Medicines is a Cambridge, Massachusetts-based biotechnology company developing kinase inhibitors for systemic mastocytosis, other mast cell-driven diseases and cancer. Its approved medicine AYVAKIT (avapritinib) treats systemic mastocytosis and certain gastrointestinal stromal tumors. Sanofi acquired the company in July 2025.
Key facts
| CAGE Code | 6NX60 |
|---|---|
| Legal Name | Blueprint Medicines Corporation |
| Company Operating Status | Acquired |
| Full Address | Baarerstrasse 8 6300 Zug Switzerland |
| Stock Symbol | BPMC |
| Ticker Symbol | BPMC |
| Wellfound ID | blueprint-medicines |
| Wikidata ID | Q56582970 |
Contact details
Email and phone for Blueprint Medicines are available to signed-in members of CliffBio.
Sign in to view